Impact of cannabis use on Schizo-affective disorder

Introduction Schizoaffective disorder (SAD) is a nosographic entity characterized by an association of schizophrenic symptoms with thymic episodes. Addictive substance abuse behaviours precede or appear concomitantly and/or for the majority patients. Objectives The objective our work was to specify sociodemographic ,clinical and therapeutic characteristics this population compare them group patients who do not use cannabis. Methods This retrospective descriptive study Disorder meeting criteria Diagnostic Statistical Manual Mental Disorders American Psychiatric Association, 5th Version (DSM-5), hospitalized between January 2015 December 2021 in psychiatry department EPS Tahar Sfar Mahdia. Results Our sample composed two groups: A first formed positive toxicological assessment tetra-hydro-cannabinol (n=14) second witha negative (n=36). In SAD subjects using cannabis, average age at hospitalization younger (27.5 years) than other groups, earlier (27.27 vs 33.58; p=0.04), duration number days greater (29.33 vs. 24.67; p=0.02) they had required during their hospital stay higher dosage antipsychotics equivalent doses chlorpromazine (723 603; p=0.04). There significant difference (p ≤ 0.04) psychometric scales (BPRS, SAPS SANS) favour did Conclusions deleterious psychic effects chronic cannabis have long been suspected time. Patients followed present more frequently reference addictive towards which associated many events affecting clinical symptomatology, evolution, prognosis response. Disclosure Interest None Declared